Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Celldex Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
CLDX
Nasdaq
2836
https://celldex.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Celldex Therapeutics, Inc.
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
- Apr 9th, 2024 1:35 pm
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
- Apr 8th, 2024 4:00 pm
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
- Apr 8th, 2024 1:35 pm
Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?
- Mar 20th, 2024 1:55 pm
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
- Mar 8th, 2024 12:00 pm
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
- Mar 5th, 2024 3:30 pm
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Mar 5th, 2024 3:10 pm
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
- Mar 1st, 2024 2:14 am
Celldex (CLDX) Upgraded to Buy: What Does It Mean for the Stock?
- Feb 29th, 2024 5:00 pm
Wall Street Analysts Predict a 26.53% Upside in Celldex (CLDX): Here's What You Should Know
- Feb 29th, 2024 2:55 pm
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
- Feb 28th, 2024 9:01 pm
Celldex Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
- Feb 27th, 2024 11:18 am
Celldex Stock Rockets 28% On A Promising New Hives Treatment
- Feb 26th, 2024 9:03 pm
Celldex Therapeutics (CLDX) Reports Q4 Loss, Tops Revenue Estimates
- Feb 26th, 2024 1:10 pm
Celldex Therapeutics Inc (CLDX) Reports Q4 and Full Year 2023 Financial Results
- Feb 26th, 2024 12:32 pm
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
- Feb 26th, 2024 12:01 pm
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
- Feb 24th, 2024 7:05 pm
TipRanks’‘Perfect 10’ List: These 2 Biotech Stocks Look Compelling at Current Levels
- Feb 20th, 2024 1:26 pm
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Feb 6th, 2024 9:01 pm
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
- Feb 5th, 2024 1:01 pm
Scroll